These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 12525525)

  • 1. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
    Vokes EE; Stenson K; Rosen FR; Kies MS; Rademaker AW; Witt ME; Brockstein BE; List MA; Fung BB; Portugal L; Mittal BB; Pelzer H; Weichselbaum RR; Haraf DJ
    J Clin Oncol; 2003 Jan; 21(2):320-6. PubMed ID: 12525525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
    Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.
    Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Ferreli L; Camboni P; Lusso MR; Mocci M; Madeddu C; Mura L; Mudu MC; Proto E; Tore G; Mura M; Macciò A; Ferreli A; Amichetti M
    Oncol Rep; 2003; 10(3):759-66. PubMed ID: 12684655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
    Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
    Kies MS; Haraf DJ; Rosen F; Stenson K; List M; Brockstein B; Chung T; Mittal BB; Pelzer H; Portugal L; Rademaker A; Weichselbaum R; Vokes EE
    J Clin Oncol; 2001 Apr; 19(7):1961-9. PubMed ID: 11283128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
    Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
    Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
    Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
    Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
    Vokes EE; Kies MS; Haraf DJ; Stenson K; List M; Humerickhouse R; Dolan ME; Pelzer H; Sulzen L; Witt ME; Hsieh YC; Mittal BB; Weichselbaum RR
    J Clin Oncol; 2000 Apr; 18(8):1652-61. PubMed ID: 10764425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
    Kies MS; Haraf DJ; Athanasiadis I; Kozloff M; Mittal B; Pelzer H; Rademaker AW; Wenig B; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1998 Aug; 16(8):2715-21. PubMed ID: 9704722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
    Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
    Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
    Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
    Milano MT; Vokes EE; Kao J; Jackson W; List MA; Stenson KM; Witt ME; Dekker A; MacCracken E; Garofalo MC; Chmura SJ; Weichselbaum RR; Haraf DJ
    Int J Oncol; 2006 May; 28(5):1141-51. PubMed ID: 16596230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV).
    Wanebo HJ; Chougule P; Ready N; Koness RJ; Akerley W; McRae R; Nigri P; Leone L; Webber B; Safran H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):77-84. PubMed ID: 10210544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
    Brockstein B; Haraf DJ; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman SM; Ratain MJ; Sulzen L; Klepsch A; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1998 Feb; 16(2):735-44. PubMed ID: 9469365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.